IPO Databook: BirchBioMed (BRBM US) - Oct 2026

83 Views11 Oct 2026 10:30

SUMMARY

BirchBioMed Inc. is a clinical stage biopharmaceutical company developing treatments for scarring, skin disorders, autoimmune diseases, and organ fibrosis.
BirchBioMed completed a Phase 1 clinical trial for FS2 in 2018 and received U.S. FDA Orphan Drug Designation for FS2 in November 2025.
The company reported cash and cash equivalents of $3,086,484 as of June 30, 2026, alongside a net loss of $(1,249,402) for the six months then ended.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream